NCT02806505View on ClinicalTrials.gov

HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Peginterferon alfa-2a

Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.

Trial Locations (22)

1090

Vienna

8036

Graz

11527

Athens

13385

Marseille

18354

Nikaia

20119

Medan

31059

Toulouse

34303

Istanbul

34390

Istanbul

34662

Istanbul

35040

Izmir

67091

Strasbourg

75747

Paris

94010

Créteil

94275

Le Kremlin-Bicêtre

70335-000

Brasília

90035-003

Porto Alegre

15090-003

Sao Jose Rio Preto

78048-790

São Luís

04023-900

São Paulo

09134

Cagliari

Unknown

Abu Dhabi

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02806505 - HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD) | Biotech Hunter | Biotech Hunter